Company news

Share this article:

Coley Pharmaceutical Group will receive $5 million from Dynavax Technologies Corporation in return for rights to market Coley's hepatitis B vaccine Heplisav. The vaccine is currently in Phase III clinical trials and Coley expects to submit it to the FDA next year. Coley is eligible for an additional $5 million payment upon US approval of the vaccine.

Advancis Pharmaceutical Corporation has changed its name to MiddleBrook Pharmaceuticals. The name change was completed pursuant to the company's jointly submitted Permanent Injunction and Order with Sanofi-Aventis of October 27, 2006, whereby the company agreed to cease using the Advancis name by June 30, 2007. In conjunction with the new name, the company has changed its NASDAQ trading symbol to MBRK, effective the start of trading on June 29.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.